The research identifies a novel subset of cancer-associated fibroblasts (CAFs), termed PTGER3+ lipoCAFs, which are induced by chemotherapy in bladder cancer. Unlike typical stromal cells that shield tumors, these fibroblasts undergo metabolic reprogramming to enhance lipid oxidation, specifically using the enzyme CYP1B1 to convert arachidonic acid into the metabolite 11-HETE. This secreted molecule acts as a natural inhibitor of PTEN within CD8+ T cells, triggering the AKT/mTOR signaling pathway to boost immune activation and tumor-killing efficiency. Clinical data demonstrates that patients with a higher abundance of these lipoCAFs experience significantly better chemotherapy responses and prolonged survival. Furthermore, the study suggests that supplementing treatment with 11-HETE or its precursors can synergistically improve the efficacy of both chemotherapy and immunotherapy. These findings reveal a critical stromal mechanism that transforms the tumor microenvironment into an immune-promoting landscape during cancer treatment.

References:

• Ma Z, Wang Y, Wang W, et al. Lipid oxidation reprogramming in cancer-associated fibroblasts enhances CD8+ T cell cytotoxicity and therapeutic response[J]. Cancer Cell, 2026.